Skip to content
HeyJared

Philip MacKellar

Reporter · CA

Indexed articles, last 90 days
6
Latest publication
Sep 2, 2026
Outlet visibility, for Theglobeandmail
Top 10K sites
Earliest in this view
Jul 16, 2026

Latest articles

  1. Article · Sep 2, 2026 · Philip MacKellar

    Aurora Cannabis urges shareholders to reject hostile takeover offer by Curaleaf (opens the original)

    Excerpt · Critical tone · English

    Read excerpt

    Aurora Cannabis Inc. ACB-T is urging its shareholders to reject a hostile takeover bid by Curaleaf Holdings, Inc. CURA-T, saying the unsolicited offer undervalues Aurora and is not in the best interests of shareholders. Aurora says it is debt free and has about $149-million in cash, while Curaleaf has over $1-billion in debt and would gain control over its cash without paying fairly. Miguel Martin, executive chairman and CEO of Aurora, says Curaleaf is attempting to use Aurora shareholders’ own

  2. Article · Aug 25, 2026 · Philip MacKellar

    Contra Guys: The case for Cronos Group as a contrarian bet on pot stocks (opens the original)

    Excerpt · English

    Read excerpt

    Pot stocks have been on our radar for years. Before the pandemic, the sector was booming. Initial public offerings involving cannabis companies hit the market amid widespread hype and fanfare. For a while, no valuation, analyst scrutiny, or level of insider selling could undo the momentum or feel-good story associated with the legalization of marijuana. Then the boom turned to bust. In 2022, many names were down more than 90 per cent, and we argued the sector was contrary but uninvestable. This

  3. Article · Aug 18, 2026 · Philip MacKellar

    Curaleaf launches $260-million takeover bid for Aurora Cannabis (opens the original)

    Excerpt · English

    Read excerpt

    U.S.-based cannabis firm Curaleaf Holdings said on Tuesday it has launched a takeover bid for Aurora Cannabis valuing the Canadian peer at about US$260-million, a week after it first announced the proposal. U.S.-listed shares of Aurora rose 3 per cent in early trading. Aurora shareholders will get 0.3463 Curaleaf shares and 75 cents in cash for each Aurora share, amounting to a total consideration of US$4 per share. The offer is capped at US$5 per share if Curaleaf’s stock rises above a set leve

  4. Article · Aug 11, 2026 · Philip MacKellar

    Curaleaf to launch takeover bid for Aurora Cannabis (opens the original)

    Excerpt · English

    Read excerpt

    Curaleaf Holdings Inc. CURA-T says it intends to launch a takeover bid for Edmonton-based cannabis company Aurora Cannabis Inc. ACB-T Curaleaf said in a news release on Tuesday it plans to make an offer to purchase all of Aurora’s issued and outstanding common shares. If successful, the move would create a combined cannabis company with a footprint in 17 countries across Europe, North America and other international markets, it said. The Stamford, Conn.-based company said it is going public with

  5. Article · Jul 28, 2026 · Philip MacKellar

    Contra Guys: Why we think there’s still a compelling case to buy this 6%-yielding Canadian stock (opens the original)

    Excerpt · English

    Read excerpt

    Sometimes it can take a long time for the market to recognize fundamental changes to a business. Take Corby Spirit and Wine Ltd. CSW-A-T, a TSX-listed beverage company that manufactures, markets and imports spirits, wines and ready-to-drink cocktails. Here at Contra the Heard, we first acquired Corby in 2021 and our average purchase price is $14.82. It was bought, at least in part, to lower the portfolio’s volatility, improve income generation and provide stability amid market uncertainty. Since

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Audience

Top 10K sites

For Theglobeandmail, the outlet · Measured Aug 1, 2026

Website popularity band, not a count of readers or article views.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about Philip MacKellar